PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

abatacept Side Effects

The reactions most often reported to the FDA for abatacept (also sold as Orencia), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

133,227
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of abatacept come from 133,227 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 133,227 reports to the FDA Adverse Event Reporting System (FAERS) for abatacept (Orencia): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

133,227

Reports Mentioning Death

8,659

6.5% of reports — not proof the medicine caused the death

Hospitalizations

24,589

18.5% of reports

Top Indication

Rheumatoid Arthritis

Most Reported Adverse Reactions

RHEUMATOID ARTHRITIS
23,596
PAIN
21,295
ARTHRALGIA
20,151
JOINT SWELLING
19,709
FATIGUE
14,200
CONTRAINDICATED PRODUCT ADMINISTERED
13,791
RASH
12,957
ARTHROPATHY
11,573
ALOPECIA
10,533
SYNOVITIS
10,151
ABDOMINAL DISCOMFORT
10,008
TREATMENT FAILURE
9,693
SWELLING
9,610
HYPERSENSITIVITY
9,413
HEADACHE
9,255
SYSTEMIC LUPUS ERYTHEMATOSUS
9,214
CONDITION AGGRAVATED
8,929

Who Reports Side Effects

Gender Distribution

Female 102,151 (85%)
Male 17,902 (15%)
Unknown 301

Age Distribution

0-17 1,929 (2%)
18-44 13,370 (16%)
45-64 37,860 (46%)
65-74 18,610 (22%)
75+ 11,249 (14%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 8,659 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 3,005
JOINT SWELLING 2,016
RHEUMATOID ARTHRITIS 2,013
INFUSION RELATED REACTION 1,966
PAIN 1,954
RASH 1,943
FATIGUE 1,892
HYPERTENSION 1,886
GLOSSODYNIA 1,883
SYSTEMIC LUPUS ERYTHEMATOSUS 1,857
TYPE 2 DIABETES MELLITUS 1,857
HEPATIC ENZYME INCREASED 1,853
SYNOVITIS 1,832
WOUND 1,824
GENERAL PHYSICAL HEALTH DETERIORATION 1,820
HAND DEFORMITY 1,814
FIBROMYALGIA 1,813
PSORIATIC ARTHROPATHY 1,785
HYPOAESTHESIA 1,776

Reactions in Hospitalization Reports

Top reactions in 24,589 reports where hospitalization was an outcome.

Reaction Reports
RHEUMATOID ARTHRITIS 5,521
PAIN 4,980
ARTHRALGIA 4,253
ARTHROPATHY 4,191
FATIGUE 4,089
RASH 4,069
SYNOVITIS 3,911
JOINT SWELLING 3,897
HYPERSENSITIVITY 3,446
DRUG HYPERSENSITIVITY 3,391
CONDITION AGGRAVATED 3,328
CONTRAINDICATED PRODUCT ADMINISTERED 3,293
INFECTION 3,189
NAUSEA 3,172
PERIPHERAL SWELLING 3,114
INFUSION RELATED REACTION 3,080
DIARRHOEA 3,018

Compare abatacept vs acetaminophen →

What the FAERS Data Reveals About abatacept Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 133,227 voluntary reports linked to abatacept and its brand equivalents (Orencia), spanning 2004 through 2025. Of those, 8,659 (6.5%) listed death as an outcome and 24,589 (18.5%) involved hospitalization. The most common indication reported alongside adverse events was Rheumatoid Arthritis.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 85% were female and 15% male; age distribution skews toward 45-64, with 37,860 reports in that bracket. The single most reported reaction is rheumatoid arthritis with 23,596 submissions, followed by pain and arthralgia.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.